Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous Progesterone for Threatened Abortion
NCT02950935Phase 3Terminated
- Sponsor
- IBSA Group
- Start
- Apr 2017
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in threatened abortion comparing Progesterone with Placebo (2 arms). Primary endpoint: Ongoing pregnancy rate at 12 weeks of gestation. Started Apr 2017; status: terminated.
02
Drugs
progesterone
03
Conditions
threatened abortion
Beyond the preview
Go deeper on NCT02950935.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02950935.